Pfizer Overpays for Seagen, but Who's Counting 0 13.03.2023 20:37 The Wall Street Journal Acquiring top biotech assets as other big pharmaceutical companies face a patent cliff was bound to be expensive. Партнёры Smi24.net Все новости за 24 часа Музыкальные новости Агрегатор новостей 24СМИ
